Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05839548

Articaine Efficacy and Safety for 3 Years Old Children

The primary purpose of this study is to determine the local anesthetic efficacy and safety of 4% Articaine compared 2% Mepivicaine in 3 years old children, by using infiltration technique for primary teeth that required restorative, pulp therapy, or dental extraction procedure, as assessed by measuring the pain experience during injection and treatment procedures, child's behavior during the procedure, and postoperative complications.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

36 month–47 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Qassim University

Burayadh, Al-Qassim Region, 51452, Saudi Arabia

About this study

Articaine has been widely used in dental surgery. Dentists started to use carticaine around 1977. In dentistry, articaine has been investigated extensively. Clinical trials comparing articaine mostly with lidocaine have varied in study design and site of action. The overwhelming majority of references in the literature describing the alleged neurotoxicity of articain concern paraesthesia and prolonged numbness after dental procedures. An excellent review of the dental literature was published last year. The authors concluded that articaine is a safe and effective local anesthetic drug to use in all aspects of clinical dentistry for patients of all ages, with properties comparable to other common local anesthetic agents. Although there may be controversy regarding its safety and advantages in comparison to other local anesthetics, there is no conclusive evidence demonstrating neurotoxicity or significantly superior anesthetic properties of articaine for dental procedures. The choice whether to use articaine or another local anesthetic is based on the personal preference and experiences of individual clinicians. 3Currently, articaine is available as a 4% solution containing 1:100,000 or 1:200,000 epinephrine. Clinical trials comparing 4% with 2% solutions show no clinical advantage of 4% over a 2% solution.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients have to meet all of the following inclusion criteria. They are eligible if:

  • They are Healthy (ASA 1: no acute or chronic disease, normal BMI percentile for age.
  • They are 36 to 47 months old children.
  • Intellectually qualified for communication.
  • They have under gone either clinically indicated gingival abscess, dental caries or pathological root resorption or periapical radiolucency showing on the radiograph.
  • Child's body weight at least 15 kg.
  • Ability to communicate effectively in the Arabic or English language.
  • Not taking any agents likely to interfere with reporting of pain (analgesics).
  • Needs any of the following procedure: Class I cavity, Class II cavity, pulpotomy, pulpectomy, stainless steel crown (SSC) or extraction.
  • Prior to enrollment, all radiographic data must be found acceptable by pediatric dentist.
  • Written and singed informed consent from legally acceptable representative.

Exclusion criteria

Patients are excluded from the study if:

  • Patients have allergic to local anesthetic with epinephrine (sulphites or amide).
  • Intellectual or severe emotional problems. patient with intellectual development is significantly lower than average and his or her ability to adapt to the environment is consequently limited like autism, Down syndrome, fragile x syndrome, fetal alcohol syndrome, and Prader-Willi syndrome.
  • Considerable behavior problems.
  • Parents refuse participation in the trial.
  • History of previous bad dental experience.
  • Primary tooth who had a history of failed pulp therapy.
  • They have uncontrolled medical condition.
  • They use immunosuppressive agents, rifampin, or anticonvulsants, or any other medication.
  • Glucose 6 phosphate dehydrogenase deficiency.
  • Congenital cardiac diseases.
  • Seizures or uncontrolled epilepsy.

Treatment and study plan

Mepivacaine 2% with epinephrine 1:100,000

Drug

Local Anesthesia

Other names: medicaine 2%

Articaine (4%) with epinephrine 1:100,000

Drug

Local Anesthesia

Other names: septanest 4%

Primary outcomes

  1. Change in systolic and diastolic blood pressure (mmHg).

    Time frame: 5 minutes before, during, and after 30 minutes of dental procedure.

    Normal blood pressure, defined as a systolic pressure less than 120, and a diastolic pressure less than 80.

  2. Change in pulse rate (beats per minute).

    Time frame: 5 minutes before, during, and after 30 minutes of dental procedure.

    Pulse rate is the frequency of the heartbeat measured by the number of contractions of the heart per minute.

  3. Change in respiratory rate (breaths per minute).

    Time frame: 5 minutes before, during, and after 30 minutes of dental procedure.

    The respiration rate is the number of breaths a person takes per minute.

  4. Dental pain assessment: Frankl Behavior Rating Scale (FBRS).

    Time frame: up to 30 minutes after dental procedure.

    Frankl Behavior Rating Scale (FBRS) dichotomized into definitely negative (1), negative (2), positive (3), definitely positive (4).

  5. Dental pain assessment: Faces, Legs, Activity, Cry, and Consolability. (FLACC).

    Time frame: up to 30 minutes after dental procedure.

    Each category is scored on the 0-2 scale, which results in a total score of 0-10. 0: relaxed and comfortable,1-3: mild discomfort, 4-6: moderate discomfort, 7-10: sever discomfort or pain or both.

Secondary outcomes

  1. Post-operative complications.

    Time frame: 24 hours after dental procedure.

    asking the parent in next 24 hours from dental procedure, by using parents' post operative pain measure (PPPM). It will be dichotomized into absent (0-5) and present (6-15).

Sponsors and collaborators

Lead sponsor

Qassim Health Cluster

Other

Registry information

Official study title

Articaine Efficacy and Safety for 3 Years Old Children: a Clinical Randomized Control Trial

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
May 3, 2023
Registry last updated
Dec 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.